Trial Profile

A Phase 1 randomized, double-blind, placebo-controlled study of EMP-01 in healthy adult participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EMP-01 (Primary)
Indications Post-traumatic stress disorders
Focus Adverse reactions
Sponsors ATAI Life Sciences

Most Recent Events

02 Jan 2024 Status changed from active, no longer recruiting to completed, according to an ATAI Life Sciences media release.
02 Jan 2024 Results presented in the ATAI Life Scienc Media Release.
02 Jan 2024 According to an ATAI Life Sciences media release, data from this trial is expected to be presented in future medical meetings.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com